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In Iran, a developing country in south-
west Asia, an epidemiologic transition 
is underway from communicable to 
noncommunicable diseases. In Iran, 
cancer is the second largest group of 
chronic non-communicable diseases 
(NCDs) and the third most common 
cause of death following heart dis-
ease, accidents and other natural 
phenomena. There are some studies 
reporting an increasing trend in the 
incidence and mortality rate of a va-
riety of cancers in Iran. Therefore, 
controlling and preventive interven-
tions pertaining to cancers must be 
a  main priority for health policy and 
it is recommended that the high-risk 
population receive earlier screening. 
In this review, incidence and mortality 
of colorectal, lung, liver, thyroid, and 
bladder cancers in Iran are reported.
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Introduction 
Based on GLOBOCAN 2012, cancers have led to more than 14 million new 
cases and over 8 million deaths worldwide. The fraction of developing na-
tions is estimated to be 56.9% for incidence and 64.9% for deaths from can-
cers [1]. Malignancy with 14% of total deaths among the Iranian population 
is the third cause of mortality; every day 98 people succumb to the disease 
in the country [2]. There are in excess of 90,000 new cancer cases yearly in 
Iran, and it is estimated that this figure will double by the year 2020. De-
pending on the Iranian national report of cancer registry in 2009, 55.58% of 
cancer patients in Iran were male. As a result, the sex ratio reached 1.25 [3].
To date, there are more than 200 types of cancer in the world, many of 
which are happily very rare. Trends in overall incidence and overall cancer 
mortality are heavily influenced by the rather common cancers [4]. The inci-
dence of cancer in various countries is different. The five most common can-
cers (except skin cancer) in males in the world are lung, prostate, colorectal, 
stomach, and liver, but in females they are breast, lung, colorectal, cervix 
uteri, and stomach [5–7]. Also, “five common cancers (except skin cancer) in 
Iranian males were stomach, prostate, bladder, colorectal, and esophagus, 
and in females were breast, colorectal, stomach, esophagus, thyroid” [3].
The present study provides a rather comprehensive and updated picture 
of common cancer incidence and mortality based on the data available in 
Iran. Knowing what trend cancers have plays an important role in cancer 
control planning, implementation and evaluation of cancer-related interven-
tion in scientific research.
Material and methods
In this review, the data were obtained from published metaanalyses, orig-
inal research and review articles. The following terms were searched in data-
bases: Iran, tumor, cancer, mortality, incidence, prevalence, colorectal, lung, 
liver, thyroid, and bladder. The data were collected from databases such as 
Google Scholar, Scopus, PubMed, Embase, and Web of Science. The included 
studies were published before 2019.
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Results
Incidence and mortality of colorectal cancer
Morphologically, colorectal cancer (CRC) was classified 
into the multiple groups consisting of adenocarcinoma, 
carcinoma lymphoma, mucin and mucin producing, and 
other variants [8]. In a study, it was reported that in Iran, 
adenocarcinoma is the commonest histological type, after 
lymphoma and squamous cell carcinoma, and other types 
are uncommon [9]. 
Both inheritance and environment factors participate 
in the development of CRC, each to a various degree in 
different patients. It was reported that only 20–30% of CRC 
cases can be attributed to a determined inherited factor 
[10]. The remaining majority (70–80%) occur due to the life 
styles and environmental factors such as pattern of food 
consumption (low consumption of fruits and vegetables, 
daily drinking of alcohol and high intake of red meat), 
smoking and physical inactivity [11], family history, unfa-
vorable socioeconomic conditions, obesity, cooking tech-
niques [12], high body and abdominal fatness, hormone 
replacement therapy, consumption of eggs and nonsteroi-
dal anti-inflammatory drugs [13]. In addition, polyps and 
syndromes of high bowel risk such as inflammatory bowel 
diseases, particularly ulcerative colitis, must be considered 
as a risk factor for this cancer in the general population 
[13]. Also, it was reported that ethnicity can have a signif-
icant etiological role in CRC in Asia [14]. It is notable that 
the pattern of food consumption in Iranians might demon-
strate the rising incidence rate, since more recently, people 
instead of traditional foods consume more fat and fast 
food [11, 15].
CRC is the third most frequently diagnosed malignancy 
among males and the second among females worldwide 
[16]. Furthermore, it is the fourth most common causes 
of death associated with cancer across the world (8% of 
overall cancer deaths), which was calculated as more than 
1000,000 new cases each year [17, 18]. The mortality rate 
of CRC is around two per 100,000 persons per year in the 
world [19]. The highest rates of CRC are in developed na-
tions, such as the United States, Australia, Canada, and 
North-Western Europe. A low rate was found in countries 
of Asia, Africa, and South America while incidence rates 
are going up in countries previously having low incidence 
[14]. The incidence and mortality of CRC are increasing dra-
matically in Asia [18]. Westernized diet and lifestyle, espe-
cially excessive consumption of processed and red meat, 
low physical activity, and obesity have been claimed as the 
chief causes of increasing risk of CRC in lots of Asian coun-
tries [20].
In the first report in Iran, CRC was the third most fre-
quent cancer among males (ASR [age-standardised rate] = 
8.19–8.3) and the fourth among females (ASR = 6.5–7.56) 
[21]. According to the International Agency for Research 
on Cancer (IARC), the incidence rates of CRC among Ira-
nian males and females were 8.7 and 6.4 per 100,000, 
respectively, in 2008. Also, a report from the Iran Cancer 
Registry (ICR) implies that CRC is the third most prevalent 
malignancy in Iranian women and the fifth malignancy 
in Iranian men [18]. In another study, it was reported that 
CRC is the fourth main cause of death linked to cancer 
in Iran [3]. In recent study by Rezaianzadeh et al., it was 
reported that the highest and lowest ASRs were 3.4 and 
2.6 in men and 11.42 and 10.56 in women, respectively 
[22]. These difference reports are because of distribution 
of registration centers and statistical methods as well as 
sampling methods [23]. Although the incidence of CRC in 
the Iranian population is low, the incidence has continually 
increased in Iranian people during recent years [20]. More 
accurate diagnosis of CRC, changing lifestyle, diet quali-
ty, and increase of median age of the Iranian population 
are the most likely contributing factors in the increase of 
CRC in Iran [16]. In addition, the western lifestyle including 
obesity and overweight, tobacco smoking, alcohol con-
sumption, low fiber diets and low physical activity have 
been related to CRC; as recently there has been observed 
a tendency to a western lifestyle in the Iranian population 
[16]. These results demonstrate the requirement of paying 
more attention to CRC screening as a significant issue in 
health policy priorities [22].
The geographical distribution of CRC showed that its 
incidence is higher in the central and western areas of the 
Caspian Sea and the central area of Iran. This difference 
may be because of statistical methods, sampling methods, 
and distribution of registration centers [23]. In a report by 
Dolatkhah et al., it was demonstrated that the highest ASR 
is from Tehran for men (16.4) and from Zahedan for wom-
en (13.25) [20]. In Tehran, the incidence of CRC is greater 
than the estimation of World Health Organization (WHO) 
for Iran [20]. In an ecological study conducted in all the 
22 areas of Tehran, there was an association between 
CRC incidence and socioeconomic position, various food 
groups, and other risk factors such as smoking [20]. The 
crude incidence rates in both sexes were the lowest in Hor-
mozgan province, with 1.2 and 1.10, for females and males, 
respectively [24], which may be due to nutritional habits, 
i.e. high consumption of fruits and vegetables, and genetic 
factors. In addition, due to weather conditions, date fruit 
(a strong antioxidant) is widely grown and consumed in 
this area of Iran and it can potentially reduce the mor-
tality and incidence rates of most gastrointestinal tract 
malignancies [20]. There is a systematic review and meta- 
analysis on CRC incidence in Iran which can be referred to 
for detailed information on the prevalence of CRC in differ-
ent provinces [20].
There are several reports about incidence and mortality 
of CRC in Iran [11, 19, 20, 25]. In a study by Abdifard et al. 
it was reported that CRC has a rising trend in the west of 
Iran. They concluded that the increased rate of CRC may 
be attributable to rising cancer risk factors [11]. In another 
study by Ahmadi et al., it was reported that CRC patients’ 
mortality rates were 96.9 and 83 person-years among 
men and women, respectively [25]. In another study by 
Dolatkhah et al., ASR of CRC were 6.17 and 8.16 for females 
and males, respectively [20]. 
Incidence and mortality of lung cancer
According to a WHO report, primary malignancies of the 
lung are classified into eight major groups [26]; as roughly 
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88% of lung tumors are categorized in four cellular types: 
adenocarcinoma, squamous cell carcinoma (SCC), large cell 
carcinoma and small cell carcinoma [26]. In a study on ep-
idemiology of lung cancer in Ardabil, Iran, it was reported 
that unlike developed countries, SCC was the most frequent 
lung cancer, and adenocarcinoma type was less frequent 
[27]. In another study in 2014, it was demonstrated that 
lung cancers in Iran were: SCC, adenocarcinoma and small 
cell carcinoma 52.7%, 14.8% and 13.3%, respectively [28].
Smoking is the major risk factor for lung cancer [29]. 
Although it is significant in all types of lung malignancies 
and there exists a strong relationship between smoking 
and the incidence of SCC and small cell carcinoma, the 
association of smoking with adenocarcinoma is lower 
[28]. Other risk factors consist of secondary contact with 
cigarette smoke, air pollution, environmental and occupa-
tional exposure to asbestos and radon, particular metals 
(especially cadmium, arsenic, and chromium), and radio-
active materials or some organic chemical, genetic suscep-
tibility (young people), coal smoke and the spread of many 
different kinds of fuels in the household [30, 31]. Also, it 
was suggested that lung diseases such as bronchitis, em-
physema and asthma can lead to lung malignancy (partic-
ularly SCC in old age) [26].
Lung cancer is the commonest diagnosed cancer and 
the commonest cause of death related to cancer world-
wide [32]. It is estimated that lung cancer will become the 
seventh cause of death and will include 3% of the total 
deaths by 2030 [31]. Poor prognosis and high incidence of 
lung cancer have led to lung cancer being a main health 
problem during past decades. Also, the most frequent age 
for incidence of lung cancer is 55–65 years [26]. The lowest 
incidence of lung malignancy was observed in central Afri-
ca and the highest in North America [33]. It is noteworthy 
that variations in lung cancer incidence rates and trends 
among various countries or between males and females 
of a country chiefly imply differences in grade and stage of 
the tobacco epidemic [33].
Lung cancer prevalence in Iran is lower than the USA 
and Europe [28]. Despite lower frequency of lung cancer 
in Iran, the patients have a short survival [28]. In Iran, lung 
cancer, the fifth most frequent cancer, has an incidence 
rate of 4.7–9.2 per 100,000 people [30]. In a study on esti-
mation of lung cancer ASR in Iran, it was reported that the 
rate of this cancer ASR was 9.7 in 2014 and 27 in 2030 [34]. 
The reason for low incidence of lung cancer in Iran may be 
the lower rate of smoking and opiate abuse in the Iranian 
population in comparison to the world. Especially, it was 
shown that the proportion of females smokers in Iran was 
much lower than other countries [28].
According to the geographical distribution of lung can-
cer, it has been shown that this cancer is the most com-
mon in provinces of Kurdistan and West Azerbaijan. Dust 
and its distribution range may be considered for greater 
prevalence of lung cancer in the western regions of Iran. 
It is mentioned that the chief sources of dust in Iran are 
dry swamps and deserts of Iraq [23]. In another study in 
Golestan province, it was reported that the mean ASR for 
lung cancer is 11.55 (17.5 for males and 5.6 for females) 
[34]. According to results of a study in 2015, 14,403 cases 
of lung malignancy were recorded, of which 10 582 cases 
were in males and 3821 in females in Iran; the greatest 
incidence rates were found in the 80–84 age group. The 
above findings demonstrated that lung cancer incidence 
in Iran is rising and is higher in males. This conclusion is 
expected because the prevalence of smoking (as the main 
risk factor for this cancer) in males is higher than females 
[32]. According to results of another study, ASR of lung 
cancer for females and males increased from 0.3 and 0.8 
per 100,000 people in 2000 to 1.5 and 4 in 2005, respec-
tively, in Iran; the highest rate of lung cancer was found in 
the mountainous area, and the lowest rate was observed 
in the western provinces of the Caspian Sea area. Howev-
er, their results showed that there is a rising trend in the 
incidence of lung cancer in all geographical regions. The 
reasons for increasing incidence of lung cancer in Iran may 
be the increasing rates of urbanization, smoking tendency, 
and environmental pollution in Iran [31].
Incidence and mortality of liver cancer
Hepatocellular carcinoma (HCC) is the most common 
type of liver cancer, which histologically arises from he-
patocytes; it represents around 90% of primary liver ma-
lignancy and 7% of all malignancies [35].
The main risk factors of HCC are HBV/HCV infection, 
exposure to aflatoxin, alcohol, non-alcoholic fatty liver 
disease (NAFLD), obesity, diabetes, cirrhosis and smoking 
[36]. Globally, hepatitis B or C viruses (HBV/HCV) are risk 
factors for around 80% of HCC cases [37]. In Iran, 80% of 
cases of developed HCC type are positive for at least one 
of the HBV markers; this virus seems to be the most fre-
quent cause of HCC in Iran [38]. Since most cases of HCC 
are due to HBV and this infection was lower common in 
Iran, the burden of HCC type is low in this country [38].
Liver cancer is amongst the most frequent malignan-
cies in the world [39]; this malignancy is the sixth most 
frequent cancer and the second leading cause of death 
relating to cancer in the world [40]. The highest incidence 
rate of liver cancer is in sub-Saharan Africa and Southeast 
Asia, and it is also rising in Europe and North America, 
which may be because the HBV infection is endemic [41]. 
Mortality of liver cancer has been quickly rising since 1970, 
because over 85% of new cases of liver cancer occur in de-
veloping countries which do not have appropriate diagnos-
tic and treatment facilities [42]. In 2013, the age-standard-
ized death rates (ASDRs) per 100,000 population for liver 
cancer were 7 and 15 in developed countries and in devel-
oping countries and the ASDRs were 7 and 16 in developed 
countries and in developing countries [43]. The greatest 
mortality and incidence of liver cancer has been observed 
in the west region of the Pacific Ocean; the mortality and 
incidence of liver cancer are around 38 times higher than 
in the East Mediterranean Sea, with the lowest mortality 
and incidence rates [40]. It is notable that differences in 
the geographical distribution of hepatitis C and B, life pat-
tern, genetic differences, and distribution of environmen-
tal carcinogens such as aflatoxin have led to differences in 
geographical distribution, time, and population of hepatic 
cancer in developing and developed countries [35].
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Iran is located in a region of low risk having an annual 
incidence less than 5 per 100,000 [44], since Iran is clas-
sified as a low endemic country for hepatitis C and B in-
fections (as the main risk factor of HCC) [45]. The mortal-
ity rates of liver malignancy per 100,000 population were 
from 4.78 in 2006 to 5.37 in 2010. The mortality rate of this 
cancer in the age groups studied demonstrated that liver 
cancer mortality increases with increasing age and most 
deaths were found in patients over 70 years old [46]. Ac-
cording to a study in 2016 on the incidence and trend of 
liver malignancy in Iran, 3584 cases of liver malignancies 
were recorded between 2003 and 2009, of which 1360 and 
2224 cases were females and males, respectively. The re-
sults of the above study showed significantly rising trends 
(p = 0.001). The above study demonstrated that the lowest 
incidence rate (i.e. 256 cases) of liver cancer occurred in 
2003 and the highest incidence rate (i.e. 950 cases) was 
in 2007 [35].
In a study by Farahmand et al., it was reported that the 
ASR of liver malignancy between 2001 and 2008 demon-
strates a 3.7-fold increase in the Fars province. Such in-
creases of liver malignancy are partly due to the rising 
trend in the incidence rate of cancer during the period 
(real changes) and partly because of the various meth-
ods of collecting information (based on population), the 
conceivable changes in diagnostic techniques, justifying 
physicians, their increased knowledge, and the related 
institutes on the importance of reporting doubtful cas-
es (unreal changes) [47]. According to data from 1999 to 
2006, the ASR of liver malignancy was rising to 0.7 and 0.2 
per 100,000 people in Kerman and all over cities of Iran, 
respectively. The lifestyle of its inhabitants, like their diet, 
increase of exposure to risk factors, and increase of life 
expectancy might increase the risk of HCC. For example, 
Kerman province generates more than 60% of pistachios 
of Iran, which used to be a major source of exposure to di-
etary aflatoxin [48]. In another study, it was reported that 
provinces such as Ardebil, Semnan, Fars, and Khuzestan 
had the greatest incidence of liver malignancy [35]. There 
are several reports on estimating the liver cancer incidence 
rate in some province of Iran [48–52].
According to data related to a study, the increased prev-
alence of liver malignancy may be because of increased 
average age, population and geographical distribution, 
and improving health and malignancy registry in Iran [35]. 
Hence, the program for the prevention and control of liver 
cancer must be a great priority for health policy makers as 
well as it being recommended that the high-risk popula-
tion receive earlier screening and vaccination [35].
Incidence and mortality of thyroid cancer
There are 4 basic categories of thyroid cancers, papil-
lary, follicular, medullary and anaplastic carcinoma, the 
first two of which are more curable compared to the oth-
ers, but medullary and anaplastic thyroid cancer comprise 
around 3% of thyroid cancers [53]. The findings of a de-
tailed study carried out in Iran indicated that thyroid pap-
illary carcinomas included 79.7% of all cases. Follicular, an-
aplastic, and medullary types constituted only 8.8%, 7.9% 
and 3.6% of all cases, respectively [54].
A wide variety of studies have investigated the etiology 
of thyroid cancer. Some leading causes linked to thyroid 
cancer are: ionizing radiation exposure, goiter and benign 
nodules/adenomas. In addition, other factors contributing 
to thyroid cancer risk include sex (hormonal and reproduc-
tive factors), height and weight at diagnosis, environmen-
tal and lifestyle factors, such as dietary habits (fish con-
sumption in endemic goiter areas, and cigarette smoking) 
and exposure to toxicants. The risk of thyroid cancer has 
also been associated with some conditions such as allergy, 
hypertension, and gallbladder disease [55]. In Iran, there is 
no comprehensive study on risk factors related to thyroid 
cancer. Iodine deficiency as a hyper-endemic condition in 
Iran contributes a rather increased incidence of thyroid 
cancer. However, the association of iodine deficiency with 
thyroid cancer is conflicting [56].
Thyroid cancer is the most frequent cancer concerning 
endocrine system in the world [57]. However, thyroid can-
cer is one of the less frequent ones, representing only 1–2% 
of all cancer types and its ASIR for more developed and 
less developed nations is 3.6 and 1.4 per 100,000 people, 
respectively [58]. This malignancy represents 2.1% of all 
new cancer cases in the world, 3.0% in the WHO Americas 
region, 2.4% in Iran, 2.2% in less developed regions, 2.1% in 
Asia, 2% in more developed regions, and 1.7% in the WHO 
Europe region [59]. A 2.3-fold growth in the thyroid can-
cer incidence has occurred in numerous countries across 
Asia, Europe, South America and Oceania, whereas some 
countries such as Norway, Sweden, and Spain have experi-
enced a decline in thyroid cancer. Southern Australia with 
177.8% malignancy incidence growth in men and 252.2% 
in women from 1973 to 2002 reported the highest increase 
in the thyroid cancer [60]. Thyroid cancer cases having 
been increasing worldwide during the past decades, such 
remarkable growth in its incidences stems mainly from 
early detection of even small tumors by advanced appa-
ratus and methods [61]. The reason(s) behind the global 
rise in thyroid cancer are still elusive. There has been a lot 
of controversy about the determinants of the worldwide 
increase of thyroid cancer incidence. Diagnostic intensi-
ty is considered to be the leading factor responsible for 
the carcinoma incidence increase. Another major source 
of its increasing incidence is attributable to environment 
and lifestyle changes [61]. Its 5-year survival rate varying 
by patient age and stage of disease ranges from about 85 
to 100% [53]. Taken together, 40,000 deaths from thyroid 
cancer occurred in 2012 worldwide. However, thyroid can-
cer mortality has declined over the last 10 years, due to 
variations in risk factor exposure, medical advances, diet 
enrichment and earlier detection [58]. Compared to most 
other adult cancers, thyroid cancer often occurs at young-
er ages. Meanwhile, some studies have revealed that no 
statistically significant difference has been found in the 
incidence of thyroid malignancy between young and adult 
patients [62]. According to statistics from GLOBOCAN 
2012, thyroid cancer mortality is 0.5% worldwide. Thyroid 
cancer represents 0.4% of mortality in more developed re-
gions, 0.6% in less developed regions, 0.5% in Asia, 1.1% in 
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Iran, and 4% in the WHO Europe and Americas region [59]. 
Thyroid cancer is much more common in women (230,000 
new cases) than in men (70,000 new cases) [58].
Among the Iranian population, thyroid cancer is the 7th 
most frequent one in women, 14th in men and the 11th most 
common in both sexes [63]. In a study by Haghpanah et al., 
the ASR for thyroid cancer was 1.289 (1.59 for females, 
0.627 for males) [64]. According to a study in 2015 on the 
incidence rate and trend of thyroid cancer in the Iranian 
population, it was reported that there was an increase in 
incidence of thyroid cancer over 2003–2009. Furthermore, 
the ASR for males and females increased from 0.82 and 2.02 
to 1.36 and 4.2 per 100,000, respectively [59]. Although en-
hanced detection is related to the increased thyroid cancer 
incidence during the past decades, it cannot entirely clarify 
the reason for the increase [59, 65]. In another study per-
formed in 2016, the incidence rate of thyroid cancer was 
reported as 2.20 per 100,000 persons between 2004 and 
2010 in the Iranian population [66]. The highest prevalence 
rate of thyroid cancer was among those aged 45 years at 
the time of diagnosis. Furthermore, a dramatic fall was ob-
served in the rate of thyroid cancer among children less 
than 19 years old [66]. Mean age of Iranian patients at di-
agnosis is around 43 years, implying earlier occurrence of 
thyroid cancer in Iranians in comparison to most countries 
in the world [67]. In a study on thyroid cancer patients in 
Iran, the female to male ratio was 1.8, while it was 1.3 in 
anaplastic carcinomas due to its higher prevalence among 
men [67]. It was reported that one-, two-, three-, four- and 
five-year survival rates of thyroid cancer in Iran were 95%, 
92%, 91%, 90% and 88%, respectively [68].
In a study on data of four Iranian provinces (Kerman, 
Mazandaran, Gilan and Golestan) during 1996–2000, it 
was found that the highest incidence rate of thyroid cancer 
is in Kerman (ASR of 1.643) and the lowest incidence rate 
in Golestan (ASR of 0.735) [64]. Mehrabani et al. examined 
the occurrence of thyroid cancer in Fars province (southern 
Iran). They reported that the ASR per 100,000 population 
was 0.52 and 0.83 in males and females, respectively [69]. 
In another study by Khayamzadeh et al., the best surviv-
al in the patients with thyroid cancer was reported in the 
southwest area (Khuzestan), but the worst in northwest 
(Azarbaijan) [68]. Hajizadeh et al. investigating the ASR for 
thyroid cancer incidence (per 100,000) from all provinces 
in Iran revealed that in total Isfahan, East Azarbaijan, Fars, 
and Chaharmahalbakhtiari had the highest but Qom, Sis-
tanbalochestan, and Semnan the lowest incidence rate in 
2008 [59]. Ardakani et al. estimated survival of patients 
suffering from thyroid cancer in Yazd, Iran. Their findings 
revealed that survival rates at the end of 1, 3, and 5 years 
were 99%, 96%, and 91%, respectively. Furthermore, the 
lowest survival rate was observed in patients with the an-
aplastic type and stage IV of thyroid carcinoma [57].
Since many cases of thyroid cancer are curable suc-
cessfully, diagnosis of this malignancy at early stages is 
expected. Moreover, attention to high-risk groups and 
public awareness programs are necessary to reduce the 
incidence of thyroid cancer in future. On the other hand, 
the use of radioactive iodine therapy can lead to increas-
ing the survival rate in patients having thyroid cancer. 
Incidence and mortality of bladder cancer
In terms of morphology, in developed countries, tran-
sitional cell carcinoma (TCC) is the commonest kind of 
bladder cancer (90%), following SCC (5%), and adenocarci-
nomas (2%). However, in developing countries, SCC is the 
most common type (75%) of bladder cancer [70]. In Iran, 
it was reported that bladder TCC, papillary TCC, adeno-
carcinoma, carcinoma, and SCC include 43.89%, 49.86%, 
1.20%, 0.49%, and 1.14% of all cases, respectively [71].
Development of approximately half of all bladder can-
cers is attributable to smoking [72]. There are associations 
between risk of developing bladder cancer and occupa-
tional exposure to aromatic amines and polycyclic aromat-
ic hydrocarbons. However, little is known about the impact 
of environmental pollution and diet on incidence of blad-
der cancers [73]. Other suspected risk factors reported to 
contribute to developing bladder cancer include high body 
mass index, behavioral elements, and genetic factors [74]. 
In a study on factors contributing to bladder cancer in 
Iranians, it was reported that pickles and vegetables had 
protective effects. In addition, histories of all evaluated 
diseases were accompanied by increased risks for bladder 
cancer. Cigarette smoking, opium use, history of excessive 
analgesic use and hair dye use had significant correlations 
with bladder cancer occurrence [75]. It is notable that since 
there are more than one million opium abusers in Iran, 
high use of opium and its derivatives among Iranian peo-
ple has been known as the most important risk factor for 
bladder cancer incidence [76, 77]. 
Bladder cancer with an estimated 382,700 new cases 
(294,400 in males and 88,300 in females) and 150,300 
deaths in 2008 is the 11th most common and the 14th main 
cause of cancer-related deaths worldwide [78]. Depending 
on the differences in risk factors, incidence and mortality 
rates of bladder cancer vary from one country to another 
[78]. The highest incidence rates of bladder cancer among 
men have been observed throughout southern, western 
and northern Europe, North America, and Oceania; rela-
tively low rates are observed in Eastern Europe, Central 
America, South America, and a number of areas of Asia 
[79]. The findings of a study by Chavan et al. revealed that 
the maximum incidence rates belong to developed coun-
tries and some regions of Africa, while the highest mortal-
ity rates are in Middle Eastern nations and North African 
[80]. Recently, a downward or stable trend in bladder can-
cer incidence rates has been observed in many Western 
countries [81]. Furthermore, prevalence and incidence of 
bladder cancer rise with age, as the peak incidence is in 
the 7th and 8th decades of life [82]. The bladder cancer mor-
tality rate is 10 per 100,000 for males and 2.4 per 100,000 
for females [83]. It is notable that the stage of malignancy 
and development levels of a region have an impact on the 
mortality rate of bladder cancer [70]. Moreover, mortality 
patterns of bladder cancer have been declining or stable 
across most parts of Europe and China. The reduction in 
smoking prevalence has made a huge contribution to the 
fall of bladder cancer incidence [81]. Bladder cancer inci-
dence is about 4 times higher in men than women. The 
difference in incidence according to gender has been esti-
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mated to be largely attributed to the higher prevalence of 
tobacco smoking among men [84]. A comparison of blad-
der cancer between sexes has shown high male-to-female 
ratios in the northern African region (e.g. Egypt) and West-
ern countries [80]. 
Bladder cancer is the sixth most frequent malignancy 
in the Iranian population with an estimated ASIR of 8.4 
per 100,000 people and ranks as the second malignancy 
site among Iranian men [85]. This malignancy is also the 
main genitourinary malignancy, with an increase of ASR 
from 2.12 in 2003 to 3.28 in 2009 [86]. Hosseini et al. in-
vestigated the relationship between bladder cancer and 
opium consumption in an Iranian population. Their results 
showed that there is approximately a 5-fold surge in risk of 
developing this malignancy with opium consumption [77]. 
In a recent study, it was reported that the incidence rate of 
bladder cancer in the Iranian population is rising. This in-
crease may be due to improvements in the cancer registra-
tion system, lifestyle, increase of life expectancy and other 
risk factors [87]. In another study, Mahdavi et al. evaluated 
mortality rates of bladder cancer per 105 persons and re-
ported that the death rate from bladder cancer decreased 
from 1.12 to 1.09 over a five-year period (2006–2010). In 
addition, Mahdavi et al. reported that the mortality rates 
in men, during that time span, increased with age [88]. 
In a recent report on the histological and epidemiological 
trend of bladder malignancy in Iran, it was revealed that 
there is an increasing trend in ASIR of bladder cancer, so 
that the ASIR increased from 2.12 to 3.78 in females and 
from 8.35 to 14.42 in males per 100,000, which was signif-
icant for both sexes [71].
The geographical distribution map of bladder cancer in 
terms of ASIR in 2005 revealed that Yazd, Kurdistan, Gilan 
and Fars have the highest but Hormozgan, Hamedan, and 
Sistan-Baluchestan provinces the lowest incidence [23]. 
In a study, Talaiezadeh et al. reported bladder cancer in-
cidence in Khuzestan province (Southwest of Iran). Their 
data indicated that bladder cancer is the fifth (with ASR 
of 4.07 per 100,000) and the second (with ASR of 10.7 per 
100,000) most common malignancy in males and males, 
respectively [89]. In a study, Ahmadi et al. evaluated socio-
economic and epidemiologic status of bladder malignancy 
in Mazandaran province (northern Iran) and reported that 
bladder cancer is often observed in the elderly and the men 
to women ratio was 8. Furthermore, Ahmadi et al. showed 
that macroscopic hematuria is a remarkable symptom 
for detecting bladder cancer, likely urothelial tumor, that 
should be followed up in patients with transabdominal 
ultrasonography [83]. In another study by Ramezani et al. 
on clinicopathological and epidemiological features of 
bladder cancer in Kermanshah province (west Iran), it was 
found that bladder cancer is a common cancer often di-
agnosed in older adults, so that 90.5% of patients were 
aged over 40 years and 81.4% were older than 50 years 
[90]. Salehi et al. investigated the epidemiology of bladder 
cancer in Shiraz (southern Iran) and reported that opium 
and tobacco use were found in 34.1% and 65.3% of pa-
tients, respectively. Furthermore, transitional cell carcino-
ma (95.7%) was the most common type of bladder cancer 
[91]. Somi et al. reported a bladder cancer ASR of 3.68 and 
15.72 for females and males during the years 2006–2007 
in east Azerbaijan [92]. In a recent study on prevalence of 
bladder cancer in Isfahan Province, Iran, a 28.6% increase 
in the incidence rate of this cancer was reported over the 
years 2011–2015 [93]. Keyghobadi et al. evaluated the ep-
idemiology and trends of bladder cancer in the province 
of Kerman (southeast of Iran). They reported that bladder 
cancer was the third most common cancer in both sexes 
during a six-year period (2004–2009) and the second most 
prevalent cancer in males and its incidence increased be-
tween 2004 and 2009 (from ASIR of 7.73 in 2004 to 14.66 
in 2009) [94].
Given the growing trend in bladder cancer incidence, it 
is recommended that health policies should be adopted in 
order to prevent the respective risk factors such as tobac-
co and harmful industrial materials. In addition, the use 
of hematuria home screening can lead to decreasing mor-
tality from bladder cancer. Furthermore, it is necessary to 
be given public education related to the long-term side ef-
fects of opium abuse as well as screening for bladder can-
cer among opium and tobacco abusers at younger ages.
Conclusions
Colorectal cancer (CRC) is the fourth most common 
cause of cancer-related deaths worldwide. The incidence 
of CRC remarkably differs based on the geographical areas. 
In addition, there is a considerable divergence in the mor-
tality and incidence rates of CRC between various racial 
and ethnic groups. There is an increasing trend in CRC inci-
dence in low-risk countries such as Iran. Earlier screening 
and change in the life-style can be effective methods to 
reduce the burden of CRC. Generally, it is recommended 
that onset of screening programs for CRC at age 50 for 
average-risk individuals would be appropriate, while for 
those at high risk, earlier screening is suggested.
Globally, lung cancer is the most commonly diagnosed 
cancer and the commonest cause of cancer-related death 
in the world. It is known as one of the costliest illnesses. 
Poor prognosis and also high incidence have made lung 
cancer a main health problem in the world over the past 
decades. The lung cancer incidence in men more than 
women is likely due to the smoking pattern. The lung can-
cer prevalence in Iran is lower than in the USA and Europe. 
The increasing lung cancer incidence rate in Iran is occur-
ring along with increasing environmental pollution, rates 
of urbanization, and smoking tendency. Therefore, imple-
mentation of policies related to effective tobacco control 
can be a way of reducing lung cancer prevalence. 
Liver cancer is amongst the most frequent malignancies 
in the world. The highest incidence rates of liver cancer are 
in sub-Saharan Africa and Southeast Asia, and the rates 
are also rising in Europe and North America, which may 
be due to HBV infection being endemic. Iran is located in 
a region of liver cancer low risk, owing to a low endemic 
prevalence of hepatitis C and B infections. The ASIR of liver 
cancer in Iran is increasing, which may be due to increas-
ing average age, population and geographical distribution, 
as well as improving cancer registry. Therefore, HBV vac-
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cination and earlier screening are needed for preventing 
liver cancer in the high-risk population.
Thyroid cancer is one of the less frequent cancers, rep-
resenting only 1–2% of all cancer types. A 2.3-fold growth 
in the thyroid cancer incidence has occurred in numerous 
countries across Asia, Europe, South America and Ocea-
nia. Among the Iranian population, thyroid cancer is the 
11th most common in both sexes. The thyroid cancer inci-
dence increased during the past years. Mean age of Irani-
an patients at thyroid cancer diagnosis is around 43 years, 
implying earlier occurrence of thyroid cancer in Iranians in 
comparison to most countries in the world. So, diagnosis 
of thyroid cancer at early stages is expected. Furthermore, 
radioactive iodine therapy can lead to increasing the sur-
vival rate in patients with thyroid cancer. 
Bladder cancer is the 11th most common and the 14th 
main cause of cancer deaths in the world. Depending on 
the discrepancy in risk factors, incidence and mortality 
rates of bladder cancer vary from one country to anoth-
er. Bladder cancer is the sixth most frequent malignancy 
in the Iranian population and ranks as the second malig-
nancy site among Iranian men. It was reported that the 
incidence rate of bladder cancer in the Iranian population 
is rising. There is approximately a 5-fold surge in risk of de-
veloping bladder cancer with opium consumption. There-
fore, it is necessary to provide public education related 
to the long-term side effects of opium abuse as well as 
screening for bladder cancer among opium and tobacco 
abusers at younger ages.
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